Colistin (Polymyxin E) Inhalation Solution (Nebulizer) Suppliers & Bulk Manufacturers
Available Forms: Inhalation Solution (Nebulizer)
Available Strengths: 75 mg/2 mL
Reference Brands: Coly-Mycin M(US)
Category:
Antibiotics
Colistin inhalation solution disrupts bacterial cell membranes by binding to lipopolysaccharides, causing leakage and bacterial death. It effectively treats resistant Pseudomonas aeruginosa lung infections in cystic fibrosis patients, providing targeted, rapid bacterial eradication, improved lung function, and reduced exacerbations with minimal systemic absorption for safe, long-term pulmonary therapy.
Colistin (Polymyxin E) Inhalation Solution (Nebulizer) is available in Inhalation Solution (Nebulizer)
and strengths such as 75 mg/2 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Colistin (Polymyxin E) Inhalation Solution (Nebulizer) is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Colistin (Polymyxin E) Inhalation Solution (Nebulizer) can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Colistin (Polymyxin E) inhalation solution is approved in the EU and US for treating Pseudomonas aeruginosa lung infections in cystic fibrosis patients. In Europe, brands like Colobreathe are regulated by EMA, supported by dossiers on safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data, with generic options available. Both regions require detailed dossiers, including clinical trial results, quality practices, and pharmacovigilance plans for approval and safety monitoring. Due to its specialized pulmonary use, strict regulations on dosing, storage, and safety follow. For expert regulatory support and seamless market entry, visit PharmaTradz. We ensure compliance with European and US standards for safe, effective inhalation therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing